CN1216602C - 用于治疗糖尿病的硫辛酸和共轭酸的组合 - Google Patents

用于治疗糖尿病的硫辛酸和共轭酸的组合 Download PDF

Info

Publication number
CN1216602C
CN1216602C CN018155413A CN01815541A CN1216602C CN 1216602 C CN1216602 C CN 1216602C CN 018155413 A CN018155413 A CN 018155413A CN 01815541 A CN01815541 A CN 01815541A CN 1216602 C CN1216602 C CN 1216602C
Authority
CN
China
Prior art keywords
acid
carbon
dienoic acid
treatment
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN018155413A
Other languages
English (en)
Chinese (zh)
Other versions
CN1455670A (zh
Inventor
O·哈塞尔旺德
K·克劳默尔
K-U·鲍尔代纽斯
M·J·克拉特
L·施魏克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of CN1455670A publication Critical patent/CN1455670A/zh
Application granted granted Critical
Publication of CN1216602C publication Critical patent/CN1216602C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN018155413A 2000-09-12 2001-09-11 用于治疗糖尿病的硫辛酸和共轭酸的组合 Expired - Fee Related CN1216602C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045059.8 2000-09-12
DE10045059A DE10045059A1 (de) 2000-09-12 2000-09-12 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen

Publications (2)

Publication Number Publication Date
CN1455670A CN1455670A (zh) 2003-11-12
CN1216602C true CN1216602C (zh) 2005-08-31

Family

ID=7655916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN018155413A Expired - Fee Related CN1216602C (zh) 2000-09-12 2001-09-11 用于治疗糖尿病的硫辛酸和共轭酸的组合

Country Status (10)

Country Link
US (1) US20030187058A1 (https=)
EP (1) EP1317264B1 (https=)
JP (1) JP2004508399A (https=)
CN (1) CN1216602C (https=)
AT (1) ATE271866T1 (https=)
AU (1) AU2001284057A1 (https=)
DE (2) DE10045059A1 (https=)
DK (1) DK1317264T3 (https=)
ES (1) ES2225593T3 (https=)
WO (1) WO2002022111A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
DE602004014716D1 (de) * 2004-03-06 2008-08-14 Cognis Ip Man Gmbh Use of unsaturated fatty acids for the reduction of appetite or food intake
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
JP4556061B2 (ja) * 2006-07-27 2010-10-06 ビーエイチエヌ株式会社 ヒアルロン酸産生増強剤
CN101396357B (zh) * 2007-09-29 2010-12-29 中国科学院上海生命科学研究院 硫辛酰胺在防治胰岛素抵抗中的用途
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
EP3069612A3 (en) 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
EP2821405B1 (en) 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
CN101671331B (zh) * 2009-09-29 2011-06-01 寿光富康制药有限公司 硫辛酰维格列汀及其制备方法与应用
JP5245061B2 (ja) * 2010-05-12 2013-07-24 ビーエイチエヌ株式会社 経口用老化防止剤及び美容方法
AU2014321711B2 (en) * 2013-09-19 2019-11-14 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
WO2015050809A1 (en) * 2013-10-01 2015-04-09 Novozymes A/S Processes of producing fermentation products
CA2941518A1 (en) 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use
WO2016160594A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4343593C2 (de) * 1993-12-21 1998-05-20 Asta Medica Ag Verwendung von R-(+)-alpha-Liponsäure, R-(-)-Dihydroliponsäure oder der Metabolite sowie deren Salze, Ester, Amide zur Behandlung kompensierter und dekompensierter Insulinresistenz
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
CA2313626A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU2001234782A1 (en) * 2000-02-02 2001-08-14 Metagenics, Inc. Compositions and methods for promoting healthy joints

Also Published As

Publication number Publication date
DE10045059A1 (de) 2002-03-21
ES2225593T3 (es) 2005-03-16
ATE271866T1 (de) 2004-08-15
WO2002022111A2 (de) 2002-03-21
JP2004508399A (ja) 2004-03-18
US20030187058A1 (en) 2003-10-02
WO2002022111A3 (de) 2003-02-27
AU2001284057A1 (en) 2002-03-26
DE50103029D1 (de) 2004-09-02
EP1317264A2 (de) 2003-06-11
CN1455670A (zh) 2003-11-12
DK1317264T3 (da) 2004-11-29
EP1317264B1 (de) 2004-07-28

Similar Documents

Publication Publication Date Title
CN1216602C (zh) 用于治疗糖尿病的硫辛酸和共轭酸的组合
CN100415224C (zh) 包含脂肪酸和氨基酸的组合物
US6417233B1 (en) Ubiguinone-containing composition suitable for promoting enhanced intramitochondrial transportation of ubiguinones and methods of using same
CN102164884B (zh) 羟基丁酸酯及其医学用途
CN1160990A (zh) 配合有ω6系·ω3系不饱和脂肪酸的平衡调节剂的食品组合物
CN1684676A (zh) 富含亮氨酸的营养组合物
KR20140022888A (ko) 영양 조성물
CN1553805A (zh) 控制血糖水平的营养组合物
CN1723015A (zh) 疲劳改善剂
CN1662229A (zh) 牛磺酸治疗秃头症的应用
ZA200600799B (en) Use of pinolenic acid
JP2005510498A (ja) 食品および薬品におけるリポ酸とグルタミンの併用
CN1433275A (zh) 淀粉亚类和脂质代谢
RU2586742C2 (ru) Композиция для лечения метаболических расстройств
CN1259044C (zh) 骨代谢改善剂
CN1681514A (zh) 一种治疗糖尿病,包括与糖尿病有关的疾病和糖尿病并发症的方法
JP6053695B2 (ja) 食欲抑制剤
EP0298179A1 (fr) Nouvelles compositions riches en oligoéléments et leurs procédés de fabrication
US20250255843A1 (en) Compositions comprising cysteine prodrugs and methods using thereof
HK1056100B (zh) 来自植物的色氨酸源及其用途
HK1056100A1 (en) Tryptophan source from plants and uses therefor
JP2002234838A (ja) 体重減少および肥満処置の方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050831

Termination date: 20200911